Desjardins, A., Barboriak, D. P., Herndon, J. E., Reardon, D. A., Quinn, J. A., Rich, J. N., … Vredenburgh, J. J. (2007). Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) evaluation in glioblastoma (GBM) patients treated with bevacizumab (BEV) and irinotecan (CPT-11). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 25). AMER SOC CLINICAL ONCOLOGY.

Desjardins, A., D. P. Barboriak, J. E. Herndon, D. A. Reardon, J. A. Quinn, J. N. Rich, S. Sathornsumetee, S. Gururangan, H. S. Friedman, and J. J. Vredenburgh. “Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) evaluation in glioblastoma (GBM) patients treated with bevacizumab (BEV) and irinotecan (CPT-11).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.

Desjardins A, Barboriak DP, Herndon JE, Reardon DA, Quinn JA, Rich JN, et al. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) evaluation in glioblastoma (GBM) patients treated with bevacizumab (BEV) and irinotecan (CPT-11). In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2007.

Desjardins, A., et al. “Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) evaluation in glioblastoma (GBM) patients treated with bevacizumab (BEV) and irinotecan (CPT-11).” JOURNAL OF CLINICAL ONCOLOGY, vol. 25, no. 18, AMER SOC CLINICAL ONCOLOGY, 2007.

Desjardins A, Barboriak DP, Herndon JE, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Friedman HS, Vredenburgh JJ. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) evaluation in glioblastoma (GBM) patients treated with bevacizumab (BEV) and irinotecan (CPT-11). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2007.